Optimizing blood pressure control in patients with chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hypertension is prevalent in chronic kidney disease (CKD) patients and accelerates kidney and cardiovascular disease progression.
• Stringent blood pressure control (<130/80 mm Hg) is essential for managing CKD and reducing cardiovascular risks.
• Renin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone of antihypertensive therapy in CKD.

Purpose of the Study:

• To evaluate the efficacy of fixed-dose combination antihypertensive therapy in CKD patients.
• To compare fixed-dose combination therapy with stepped-care or sequential monotherapy.
• To explore optimal RAAS inhibitor-based combination strategies for cardiovascular risk reduction in high-risk CKD patients.

Main Methods:

• Analysis of clinical data comparing different antihypertensive treatment strategies.
• Focus on fixed-dose combinations involving RAAS inhibitors.
• Evaluation of patient adherence and achievement of target blood pressure levels.

Main Results:

• Fixed-dose RAAS inhibitor-based combinations significantly increase the likelihood of reaching target blood pressure levels compared to other strategies.
• Fixed-dose combinations can improve patient adherence by reducing pill burden and clinic visits.
• Emerging data suggest RAAS inhibitor plus dihydropyridine calcium channel blocker combinations may offer superior cardiovascular benefits over RAAS inhibitor plus diuretic combinations in high-risk patients.

Conclusions:

• Fixed-dose combination therapy, especially with RAAS inhibitors, is an effective strategy for hypertension management in CKD.
• This approach enhances treatment adherence and facilitates blood pressure control.
• Further research supports specific combination therapies, like RAAS inhibitor and dihydropyridine calcium channel blocker, for improved cardiovascular outcomes in high-risk CKD populations.